GlassScriptPhysician profile
Zanhua Yi
NPI 1144532904
$3,286.74
in general payments reported to CMS, 2019-2025
25 companies · $682 in 2025
The $682 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $397 · 2021: $641 · 2022: $258 · 2023: $645 · 2024: $195 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $447 · Honoraria: $350 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $447.15 |
| Honoraria | $350.00 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $650.00 | 2020-2021 | |
| Janssen Biotech, INC. | $602.98 | 2021-2025 | Erleada, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $537.55 | 2020-2023 | Calquence |
| Regeneron Pharmaceuticals, INC. | $350.00 | 2025 | Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $275.97 | 2019-2025 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.74 | 2019-2021 | |
| Clovis Oncology, INC. | $114.38 | 2019-2021 | |
| Tempus Ai, INC | $93.96 | 2025 | Xt Cdx |
| Verastem, INC. | $67.30 | 2019 | |
| Sobi, INC | $62.05 | 2024 | |
| Dova Pharmaceuticals | $47.45 | 2019 | |
| Taiho Oncology, INC. | $47.43 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $46.74 | 2019-2020 | |
| Amgen INC. | $30.82 | 2019-2020 | |
| Genzyme Corporation | $25.36 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $23.87 | 2021 | |
| Day One Biopharmaceuticals | $23.40 | 2024 | Ojemda |
| Pharmacyclics LLC, An Abbvie Company | $23.29 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2025 | |
| Amneal Pharmaceuticals LLC | $20.03 | 2023 | Neulasta, Avastin, Neupogen |
| Merck Sharp & Dohme LLC | $19.70 | 2019 | |
| Abbvie INC. | $19.47 | 2025 | |
| Pfizer INC. | $19.33 | 2019 | |
| Exact Sciences Corporation | $16.18 | 2025 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zanhua Yi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.